Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy

Tokumitsu,Yukio; Shindo,Yoshitaro; Matsui,Hiroto; Matsukuma,Satoshi; Nakajima,Masao; Suzuki,Nobuaki; Takeda,Shigeru; Wada,Hiroshi; Kobayashi,Shogo; Eguchi,Hidetoshi; Ueno,Tomio; Nagano,Hiroaki

doi:10.3892/ol.2019.10688

Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy

Authors:
- Yukio Tokumitsu
- Yoshitaro Shindo
- Hiroto Matsui
- Satoshi Matsukuma
- Masao Nakajima
- Nobuaki Suzuki
- Shigeru Takeda
- Hiroshi Wada
- Shogo Kobayashi
- Hidetoshi Eguchi
- Tomio Ueno
- Hiroaki Nagano
View Affiliations

Affiliations: Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755‑8505, Japan, Department of Digestive Surgery, Osaka International Cancer Institute, Osaka 541‑8567, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama 701‑0192, Japan
Published online on: July 29, 2019 https://doi.org/10.3892/ol.2019.10688
Pages: 3903-3913

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous study reported the effectiveness of the product of tumor number and size (NxS factor) as a predictor of the prognosis of patients with hepatocellular carcinoma (HCC) following hepatectomy. The aim of the present study was to validate the prognostic value of scoring systems based on the NxS factor for HCC. The records of 940 patients who underwent hepatectomy for HCC at Osaka University Graduate School of Medicine and Osaka International Cancer Institute were analyzed. The discriminatory abilities of the mathematical integrated model for tumor staging (MITS) score, which combines the NxS factor with liver function, and known prognostic systems, including the Japan Integrated Staging system, the Barcelona Clinic Liver Cancer, Cancer of the Liver Italian Program and the Tokyo system, were compared. Firstly, the present study demonstrated that a higher NxS factor was associated with decreased disease‑free survival (DFS) and overall survival (OS) in patients with HCC (P<0.05). Subsequently, univariate analysis of DFS and OS curves revealed significant differences among all NxS factor and liver damage combinations (MITS‑LD score; score 0 vs. score 1; score 1 vs. score 2; score 2 vs. score 3; all P<0.05) and all NxS factor and albumin‑bilirubin (ALBI) score combinations (MITS‑ALBI score; score 0 vs. score 1; score 1 vs. score 2; score 2 vs. score 3; all P<0.05). Furthermore, multivariate Cox proportional hazards model analysis demonstrated that there were significant differences in DFS [Hazard Ratio (HR); score 0 vs. score 1 (1.48); score 1 vs. score 2 (1.27); score 2 vs. score 3 (1.64); all P<0.05] and OS [HR; score 0 vs. score 1 (1.34); score 1 vs. score 2 (1.29); score 2 vs. score 3 (1.64); all P<0.05] among patients with different MITS‑LD scores, and there were significant differences in DFS [HR; score 0 vs. score 1 (1.38); score 1 vs. score 2 (1.43); score 2 vs. score 3 (1.60); all P<0.05] among patients with different MITS‑ALBI scores. The NxS factor may be a comprehensive measure of tumor burden for predicting the prognosis of patients with HCC following liver resection, and MITS scores could be an improved scoring system for predicting the prognosis of patients with HCC after hepatectomy.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y and Mori M: Gastroenterological surgery in Japan: The past, the present and the future. Ann Gastroenterol Surg. 1:5–10. 2017. View Article : Google Scholar : PubMed/NCBI
4	Kakeji Y, Takahashi A, Udagawa H, Unno M, Endo I, Kunisaki C, Taketomi A, Tangoku A, Masaki T, Marubashi S, et al: Surgical outcomes in gastroenterological surgery in Japan: Report of national clinical database 2011–2016. Ann Gastroenterol Surg. 2:37–54. 2017. View Article : Google Scholar : PubMed/NCBI
5	Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G and Gramlich T: AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 5:243–250. 2003. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
8	Hazama S, Tamada K, Yamaguchi Y, Kawakami Y and Nagano H: Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2:289–303. 2018. View Article : Google Scholar : PubMed/NCBI
9	Kudo M, Chung H and Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 38:207–215. 2003. View Article : Google Scholar : PubMed/NCBI
10	Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Ide N, Sawai T, Yasutake T, Nakagoe T and Nagayasu T: The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 30:765–770. 2004. View Article : Google Scholar : PubMed/NCBI
11	Harimoto N, Yoshizumi T, Sakata K, Nagatsu A, Motomura T, Itoh S, Harada N, Ikegami T, Uchiyama H, Soejima Y and Maehara Y: Prognostic significance of combined albumin-bilirubin and tumor-node-metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma. Hepatol Res. 47:1289–1298. 2017. View Article : Google Scholar : PubMed/NCBI
12	Prospective validation of the CLIP score, . A new prognostic system for patients with cirrhosis and hepatocellular carcinoma: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 31:840–845. 2000. View Article : Google Scholar : PubMed/NCBI
13	Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, et al: Proposal of a new prognostic model for hepatocellular carcinoma: An analysis of 403 patients. Gut. 54:419–425. 2005. View Article : Google Scholar : PubMed/NCBI
14	Llovet JM, Bru C and Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
15	Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T and Kudo M: Management of hepatocellular carcinoma: Report of consensus meeting in the 45th annual meeting of the Japan society of hepatology (2009). Hepatol Res. 40:667–685. 2010. View Article : Google Scholar : PubMed/NCBI
16	Yau T, Tang VY, Yao TJ, Fan ST, Lo CM and Poon RT: Development of hong kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 146:1691–1700. 2014. View Article : Google Scholar : PubMed/NCBI
17	Pons F, Varela M and Llovet JM: Staging systems in hepatocellular carcinoma. HPB (Oxford). 7:35–41. 2005. View Article : Google Scholar : PubMed/NCBI
18	Tokumitsu Y and Nagano H: Current HCC staging systems: Their uses and limitations. Hepatocellular Carcinoma: Diagnosis and treatment. Carr BI: Springer; Basel: pp. 425–442. 2016, View Article : Google Scholar
19	Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, Sakamoto K, Ueno T, Hazama S, Ogihara H, et al: An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 46:944–952. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al: Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 45:124642015. View Article : Google Scholar
21	Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
22	The general rules for the clinical and pathological study of primary liver cancer. Kanehara; Tokyo: pp. 7–41. 2010
23	Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, et al: Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J Clin Oncol. 33:550–558. 2015. View Article : Google Scholar : PubMed/NCBI
24	Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
25	Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, et al: A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett. 15:4411–4422. 2018.PubMed/NCBI
26	Mazzaferro V: Results of liver transplantation: With or without milan criteria? Liver Transpl 13 (11 Suppl 2). S44–S47. 2007. View Article : Google Scholar
27	Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 10:35–43. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI and Lee SD: A new prognostic model for hepatocellular carcinoma based on total tumor volume: The taipei integrated scoring system. J Hepatol. 53:108–117. 2010. View Article : Google Scholar : PubMed/NCBI
29	Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, Moon BS, Chon CY, Moon YM and Ahn SH: Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 97:246–252. 2008. View Article : Google Scholar : PubMed/NCBI
30	Yamashita YI, Imai K, Yusa T, Nakao Y, Kitano Y, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, et al: Microvascular invasion of single small hepatocellular carcinoma </=3 cm: Predictors and optimal treatments. Ann Gastroenterol Surg. 2:197–203. 2018. View Article : Google Scholar : PubMed/NCBI
31	Brierley JD, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 8th. Wiley-Blackwell; pp. 80–82. 2017
32	Wakabayashi H, Ishimura K, Izuishi K, Karasawa Y and Maeta H: Evaluation of liver function for hepatic resection for hepatocellular carcinoma in the liver with damaged parenchyma. J Surg Res. 116:248–252. 2004. View Article : Google Scholar : PubMed/NCBI
33	Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, et al: Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 31:1031–1036. 2016. View Article : Google Scholar : PubMed/NCBI
34	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
35	Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K and Tsuneyoshi M: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 108:768–775. 1995. View Article : Google Scholar : PubMed/NCBI
36	Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G and Tsurumaru M: Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 71:19–25. 1993. View Article : Google Scholar : PubMed/NCBI
37	Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR II, et al: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 465:96–100. 2010. View Article : Google Scholar : PubMed/NCBI